Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06209619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026 Eligibility criteria shortened, about 17 wordsv6 Show 1 more changeShow less
    • Eligibility criteria shortened, about 17 words

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria expanded, about 41 words Study description revised · Site contact updatedv5 Show 2 more changesShow less
    • Study description revised
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria revised Site contact updatedv4 Show 1 more changeShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Start date changed from estimate of Jan 30, 2024 to Jan 29, 2024 Secondary endpoints: 6 to 7v3 Show 1 more changeShow less
    • Secondary endpoints: 6 to 7

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 21, 2024 to Jan 30, 2024 · Eligibility criteria revised · Secondary endpoints revised (6) · 1 morev2 Show 4 more changesShow less
    • Start date: Jan 21, 2024 to Jan 30, 2024
    • Eligibility criteria revised
    • Secondary endpoints revised (6)
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.
Trial Details
NCT Number NCT06209619
Lead Sponsor Nathan Denlinger
Collaborators: Bristol-Myers Squibb
Conditions B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory +4 more
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov